HTA’s and access to rare diseases therapies: The view from the PID community

Pharmaceuticals Policy and Law

Volumn 13, Issue 3-4, 2011, Pages 177-181

  Prevot, Prévot ^a   Watters, D ^a  

^a Firside   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85013600810     PISSN: 13892827     EISSN: 2210495X     Source Type: Journal    
DOI: 10.3233/PPL-2011-0322     Document Type: Article

References (6)

1. H. Chapel and P.D. Arkwright, What are Immunodeficiencies? Pharmaceuticals Policy and Law, Volume 10, 2008.
2. J. Drabwell, Living life to the fullest, Pharmaceuticals Policy and Law, Volume 10, 2008.
3. P. Wood, The value of early diagnosis and treatment of patients with Primary Antibody Deficiencies, Pharmaceuticals Policy and Law, Volume 10, 2008.
4. M.L. Boyle and C. Scalchunes, Impact of IVIG treatment among Patients with Primary Immunodeficiency Diseases, Pharmaceuticals Policy and Law, Volume 10, 2008.
5. J. Modell, Primary Immunodeficiencies The Importance of Earliest Possible Diagnosis, Pharmaceuticals Policy and Law, Volume 10, 2008.
6. EUnetHTA, http://www.eunethta.eu/Public/About EUnetHTA/HTA/.